UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010614
Receipt number R000011620
Scientific Title Efficacy of once daily human GLP-1 analogue, Liraglutide on dietary lifestyle and treatment satisfaction in type 2 diabetic patients.
Date of disclosure of the study information 2013/05/01
Last modified on 2014/02/13 11:25:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of once daily human GLP-1 analogue, Liraglutide on dietary lifestyle and treatment satisfaction in type 2 diabetic patients.

Acronym

Efficacy of Liraglutide on dietary lifestyle and treatment satisfaction

Scientific Title

Efficacy of once daily human GLP-1 analogue, Liraglutide on dietary lifestyle and treatment satisfaction in type 2 diabetic patients.

Scientific Title:Acronym

Efficacy of Liraglutide on dietary lifestyle and treatment satisfaction

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Medicine in general Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm efficacy of Liraglutide on dietary lifestyle and treatment satisfaction

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Change in total calorie intake
Change in component of food (Protein, Fat, Carbohydrate)
Treatment satisfaction

Key secondary outcomes

Change in HbA1c
Change in weight and BMI
Adverse events.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Liraglutide

Interventions/Control_2

Other diabetes standard oral treatment

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

Type 2 diabetic patients who continue to visit to trial site for the treatment
Treated by diet & exercise therapy or diet & exercise therapy with oral anti-diabetic agents more than 3 months

Key exclusion criteria

Contraindication of Liraglutide
Comorbidity of endocrine disease except diabetes.
Existence of severe diabetic complication like diabetic nephropathy severer than grade III by criteria of Japan Diabetes Society and diabetic retinopathy severer than by criteria of Japan Diabetes Society.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Koichiro Yasuda

Organization

Osaka Saiseikai Noe Hospital

Division name

Department of diabetes and endocrinology

Zip code


Address

1-3-25, Furuichi, Jyoto-ku, Osaka-shi, Osaka, 536-0001, Japan

TEL

06-6932-0401

Email



Public contact

Name of contact person

1st name
Middle name
Last name Koichiro Yasuda

Organization

Osaka Saiseikai Noe Hospital

Division name

Department of diabetes and endocrinology

Zip code


Address

1-3-25, Furuichi, Jyoto-ku, Osaka-shi, Osaka, 536-0001, Japan

TEL

06-6932-0401

Homepage URL


Email

kyasuda@noe.saiseikai.or.jp


Sponsor or person

Institute

Osaka Saiseikai Noe Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

None


Other related organizations

Co-sponsor

None

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪済生会野江病院(大阪府)
Osaka Saiseikai Noe Hospital, Osaka


Other administrative information

Date of disclosure of the study information

2013 Year 05 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 02 Month 08 Day

Date of IRB


Anticipated trial start date

2012 Year 03 Month 01 Day

Last follow-up date

2013 Year 06 Month 30 Day

Date of closure to data entry

2013 Year 07 Month 31 Day

Date trial data considered complete

2013 Year 07 Month 31 Day

Date analysis concluded

2013 Year 08 Month 31 Day


Other

Other related information



Management information

Registered date

2013 Year 04 Month 30 Day

Last modified on

2014 Year 02 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011620


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name